Novavax (NVAX) Tops Q1 EPS by 55c, Revenues Beat

JPMorgan Downgrades Novavax (NVAX) to Neutral

May 12, 2021 5:45 AM EDT

JPMorgan analyst Eric Joseph downgraded Novavax (NASDAQ: NVAX) from Overweight to Neutral with a price target of $161.00 (from $285.00).

The analyst comments "We are rated Neutral on NVAX shares. While topline UK phase 3 results reported to date have shown compelling efficacy, amid a series of clinical,... More

Novavax (NVAX) Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate

May 10, 2021 9:13 AM EDT

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from a preclinical study of the company's combination quadrivalent seasonal flu vaccine (NanoFlu) and COVID-19 vaccine candidate (NVX-CoV2373). The NanoFlu/NVX-CoV2373 combination vaccine demonstrated positive immune responses to both influenza and SARS-CoV-2. A pre-print of the manuscript is available at bioRxiv.org.

The manuscript, titled 'Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike... More

Novavax (NVAX) Unlikely to Seek Vaccine Emergency Use Until June - Washington Post

May 10, 2021 8:46 AM EDT

Novavax (NASDAQ: NVAX) Unlikely to Seek Vaccine Emergency Use Until June - Washington Post

... More

UPDATE: Merkel Opposes Biden Plan to Waive Corona Vaccine Patent - Bloomberg

May 6, 2021 11:19 AM EDT

(Updated - May 6, 2021 11:23 AM EDT)

Merkel Opposes Biden Plan to Waive Corona Vaccine Patent - Bloomberg

Moderna (NASDAQ: MRNA)BioNTech SE (NASDAQ: BNTX)Pfizer (NYSE: PFE)Novavax (NASDAQ: NVAX)
... More

Novavax (NVAX) and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility

May 6, 2021 9:07 AM EDT

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to manufacture and distribute 350 million doses of NVX-CoV2373 to countries participating under the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. Under a separate purchase agreement with Gavi, the Serum Institute of India (Serum Institute)... More